Metronidazol Jelfa

Metronidazole, the active ingredient in Metronidazol Jelfa, is a Nitroimidazole antibiotic presented as a topical formulation for skin application. It is used to treat bacterial skin infections, manage rosacea, and address acne vulgaris in appropriate patients.

GNH USA supplies Metronidazol Jelfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory approvals across EU and other markets. The company ensures consistent batch integrity and on‑time delivery to meet global healthcare needs.

Metronidazole is employed in dermatologic conditions where anaerobic bacteria or protozoal organisms contribute to disease.

- Bacterial skin infections: eliminates anaerobic bacteria, reducing inflammation and promoting wound healing. - Rosacea: decreases inflammatory papules and erythema, improving facial appearance. - Acne vulgaris: limits Propionibacterium acnes overgrowth and associated inflammation, leading to fewer lesions.

Topical metronidazole may cause local reactions, though most are mild and reversible.

Common Side Effects: - Skin irritation: mild redness or discomfort at the application site. - Dryness or peeling of the skin. - Burning or stinging sensation during or after application. - Itching or mild pruritus. - Contact dermatitis: localized allergic rash.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) with swelling, difficulty breathing, or hives. - Stevens‑Johnson syndrome or toxic epidermal necrolysis presenting as extensive skin blistering. - Significant ulceration or necrosis of the treated area. - Systemic toxicity if large surface areas are applied, leading to neurological symptoms. - Unexplained fever or malaise indicating systemic involvement.

When using Metronidazol Jelfa, consider the following safety measures.

- Pregnancy: consult a healthcare provider; safety data are limited. - Breastfeeding: avoid use unless the benefit to the mother outweighs potential risk to the infant. - Known hypersensitivity: discontinue immediately if an allergic reaction occurs. - Extensive application area: monitor for signs of systemic absorption such as dizziness or neuropathy. - Open wounds or mucous membranes: avoid application unless specifically directed by a prescriber. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct light.

Metronidazol Jelfa can affect or be affected by other medicines; review the following interactions.

Major Interactions (Avoid): - Alcohol: may cause a disulfiram‑like reaction with flushing, nausea, and tachycardia. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: may raise serum lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce hormonal efficacy, requiring additional contraceptive measures. - Phenytoin: potential for increased neurotoxic side effects. - Tetracyclines: possible antagonistic effect reducing antibacterial activity.